Dear All
You may be interested to know that a report from the RATPAC trial has
just been published:
The RATPAC (Randomised Assessment of Treatment using Panel Assay of
Cardiac markers) trial: a randomised controlled trial of point-of-care
cardiac markers in the emergency department.
Health Technol Assess 2011;15(23):1–108
Conclusion
Point-of-care panel assessment increases the proportion of patients
successfully discharged home, leading to reduced median length of
initial hospital stay, but no change in mean hospital stay or total
inpatient days. Point-of-care panel assessment is associated with
increased use of coronary care and may be associated with increased use
of other interventions. Cost-effectiveness is mainly driven by
differences in mean cost, with point estimates suggesting that
point-of-care panel assessment is £211 per patient more expensive than
standard care. It is unlikely to be considered cost-effective in the
NHS, with a 0.888 probability that standard care is dominant.
Further research is required to identify factors that influence the
effectiveness and cost-effectiveness of point-of-care panel assessment,
explore alternative ways of managing patients with low-risk chest pain
and evaluate new cardiac biomarkers.
Best wishes
Douglas
Dr D Thompson
Blood Sciences
The General Infirmary
Leeds LS1 3EX
Tel 0113 3926503
Please visit our web-site at www.leedsteachinghospitals.com
------ACB discussion List Information--------
This is an open discussion list for the academic and clinical community working in clinical biochemistry.
Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content.
ACB Web Site
http://www.acb.org.uk
Green Laboratories Work
http://www.laboratorymedicine.nhs.uk
List Archives
http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html
List Instructions (How to leave etc.)
http://www.jiscmail.ac.uk/
|